Table 3. Response by type of previous treatment (ITT population).
|
Previous bortezomib |
No previous bortezomib |
|||
|---|---|---|---|---|
| KRd n=261 | Rd n=260 | KRd n=135 | Rd n=136 | |
| Best overall response, n (%) | ||||
| sCR | 31 (11.9) | 12 (4.6) | 25 (18.5) | 5 (3.7) |
| CR | 47 (18.0) | 13 (5.0) | 23 (17.0) | 7 (5.1) |
| VGPR | 97 (37.2) | 77 (29.6) | 54 (40.0) | 46 (33.8) |
| PR | 50 (19.2) | 63 (24.2) | 18 (13.3) | 41 (30.1) |
| ORR, n (%)a | 225 (86.2) | 165 (63.5) | 120 (88.9) | 99 (72.8) |
| 95% CIb | 81.4–90.1% | 57.3–69.3% | 82.3–93.6% | 64.5–80.1% |
| OR for KRd vs Rd (95% CI) | 3.60 (2.33–5.55) | 2.99 (1.55–5.76) | ||
|
Previous thalidomide |
No previous thalidomide |
|||
|---|---|---|---|---|
| KRd n=176 | Rd n=171 | KRd n=220 | Rd n=225 | |
| Best overall response, n (%) | ||||
| sCR | 32 (18.2) | 8 (4.7) | 24 (10.9) | 9 (4.0) |
| CR | 28 (15.9) | 8 (4.7) | 42 (19.1) | 12 (5.3) |
| VGPR | 63 (35.8) | 41 (24.0) | 88 (40.0) | 82 (36.4) |
| PR | 33 (18.8) | 47 (27.5) | 35 (15.9) | 57 (25.3) |
| ORR, n (%)a | 156 (88.6) | 104 (60.8) | 189 (85.9) | 160 (71.1) |
| 95% CIb | 83.0−92.9% | 53.1−68.2% | 80.6−90.2% | 64.7−76.9% |
| OR for KRd vs Rd (95% CI) | 5.03 (2.88–8.78) | 2.48 (1.54–3.99) | ||
|
Previous lenalidomide |
No previous lenalidomide |
|||
|---|---|---|---|---|
| KRd n=79 | Rd n=78 | KRd n=317 | Rd n=318 | |
| Best overall response, n (%) | ||||
| sCR | 8 (10.1) | 3 (3.8) | 48 (15.1) | 14 (4.4) |
| CR | 11 (13.9) | 1 (1.3) | 59 (18.6) | 19 (6.0) |
| VGPR | 25 (31.6) | 14 (17.9) | 126 (39.7) | 109 (34.3) |
| PR | 20 (25.3) | 21 (26.9) | 48 (15.1) | 83 (26.1) |
| ORR, n (%)a | 64 (81.0) | 39 (50.0) | 281 (88.6) | 225 (70.8) |
| 95% CIb | 70.6–89.0% | 38.5–61.5% | 84.6–91.9% | 65.4–75.7% |
| OR for KRd vs Rd (95% CI) | 4.27 (2.08–8.73) | 3.23 (2.11–4.92) | ||
Abbreviations: CI, confidence interval; CR, complete response; ITT, intent-to-treat; KRd, carfilzomib, lenalidomide and dexamethasone; OR, odds ratio; ORR, overall response rate; PR, partial response; Rd, lenalidomide and dexamethasone; sCR, stringent complete response; VGPR, very good partial response.
a
Determined by Independent Review Committee according to International Myeloma Working Group Uniform Response Criteria. Patients evaluated for ORR had a best overall response of PR or better.
b
Clopper−Pearson interval.